Predictive Oncology Announces 1-for-15 Reverse Stock Split

Core Viewpoint - Predictive Oncology Inc. will implement a 1-for-15 reverse stock split to comply with Nasdaq's minimum bid price requirement, effective September 30, 2025 [2][3]. Group 1: Reverse Stock Split Details - The reverse stock split will combine every 15 shares of common stock into one share, resulting in a reduction from 11,436,201 shares outstanding to approximately 762,414 shares [3][4]. - The reverse stock split will not change the par value per share and will affect all stockholders uniformly, with fractional shares being rounded up to the nearest whole share [3][4]. - Stockholders will receive a transaction statement from Pacific Stock Transfer, the exchange agent, detailing their new share count post-split [3][4]. Group 2: Company Overview - Predictive Oncology is focused on AI-driven drug development, utilizing its AI platform, PEDAL, which predicts with 92% accuracy the response of tumor samples to drug compounds [5]. - The company has a biobank of over 150,000 assay-capable heterogeneous human tumor samples, enhancing its drug discovery capabilities [5]. - Predictive Oncology is headquartered in Pittsburgh, PA, and aims to expedite drug development for cancer patients globally [5].